Trials
3 active
4 in total · 2 in the EU
Targets
—
None known yet
What this is
- How it works
- Boosts a chemical signal (cGMP) that relaxes blood vessels and eases strain on the heart.-ciguat: guanylate cyclase activators and stimulators WHO name stem
- Tested for
- Pulmonary Hypertension (3 trials), Vascular Diseases (3 trials), Cardiovascular Diseases (3 trials), Fibrosis (3 trials), Interstitial Lung Disease (2 trials), Lung Diseases (2 trials), Interstitial Lung Disease (ILD)
- Main trialPhase 3
- “A Phase 3, Multicenter, Randomized, Double-Blind Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Mosliciguat in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease”In the company’s words, NCT07816185 on ClinicalTrials.gov
Other drugs for Pulmonary Hypertension
- RalinepagUnited Therapeutics · Phase 3
- SeralutinibGB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. · Phase 3
- Treprostinil PalmitilInsmed Incorporated · Phase 3
- MacitentanActelion · Phase 3
- Macitentan / tadalafil FDCActelion · Phase 3
- SelexipagActelion · Phase 3
Coming up2
- DecPhase 2 trial completes · ClinicalTrials.gov
- 28 Jan 2029Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 28 Jan 2029 | A Phase 3 Trial of Inhaled Mosliciguat in PH-ILD (PHrontier) | |
| Phase 2Active, not recruiting | 26 May 2026 | A Study of Mosliciguat in PH-ILD | |
| Phase 2Recruiting | Dec 2026 | A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD | |
| Phase 1Completed | 30 Jun 2025 | A Phase 1 Study of Mosliciguat in Healthy, Adult Males |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026